Bortezomib plus melphalan and prednisone (VMP regimen) as the initial treatment for IgE multiple myeloma: a case study

被引：8
|
作者：
Sato, Hiroyuki [1 ]
Komiya, Yusuke [1 ]
Hoshino, Shigeru [1 ]
机构：
[1] Saitama Red Cross Hosp, Dept Hematol, Chuo Ku, Saitama 3388553, Japan
来源：
INTERNATIONAL JOURNAL OF HEMATOLOGY | 2014年 / 99卷 / 06期
关键词：
Multiple myeloma; IgE; Bortezomib; VMP regimen; Initial treatment; PLASMA-CELL LEUKEMIA; MAINTENANCE; THALIDOMIDE; EFFICACY; TRIAL; LEVEL; RARE;
D O I：
10.1007/s12185-014-1571-5
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Patients with IgE multiple myeloma have poor prognosis. Due to the rarity of this condition, no standard treatment has been developed. As the VMP regimen (bortezomib plus melphalan and prednisone) has been reported to be highly effective in the treatment of other types of myeloma, we treated a patient with newly diagnosed IgE myeloma using the VMP regimen. Her myeloma responded well to VMP regimen. The results of this case report thus suggest that physicians may consider VMP regimen for use as the initial treatment for IgE myeloma.
引用
收藏
页码：786 / 789
页数：4
相关论文
共 50 条
  • [41] Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairment
    Morabito, Fortunato
    Gentile, Massimo
    Mazzone, Carla
    Rossi, Davide
    Di Raimondo, Francesco
    Bringhen, Sara
    Ria, Roberto
    Offidani, Massimo
    Patriarca, Francesca
    Nozzoli, Chiara
    Petrucci, Maria Teresa
    Benevolo, Giulia
    Vincelli, Iolanda
    Guglielmelli, Tommasina
    Grasso, Mariella
    Marasca, Roberto
    Baldini, Luca
    Montefusco, Vittorio
    Musto, Pellegrino
    Cascavilla, Nicola
    Majolino, Ignazio
    Musolino, Caterina
    Cavo, Michele
    Boccadoro, Mario
    Palumbo, Antonio
    BLOOD, 2011, 118 (22) : 5759 - 5766
  • [42] Indirect Comparison of the Efficacy of Melphalan-Prednisone-Bortezomib Relative to Melphalan-Prednisone-Thalidomide and Melphalan-Prednisone for the First Line Treatment of Multiple Myeloma
    Yeh, Yating
    Chambers, James
    Gaugris, Sabine
    Jansen, Jeroen
    BLOOD, 2008, 112 (11) : 825 - 825
  • [43] BORTEZOMIB-MELPHALAN-PREDNISONE VERSUS MP AS INITIAL TREATMENT FOR VERY ELDERLY PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
    Kim, M. K.
    Kim, K.
    Yoon, D. H.
    Suh, C.
    Moon, J. H.
    Lee, Y. J.
    Lee, J. H.
    Jung, S. -H.
    Kim, H. J.
    Bae, S. H.
    Kim, J. S.
    Lee, J. -O.
    Eom, H. S.
    Lee, W. -S.
    Kang, H. J.
    Mun, Y. -C.
    Do, Y. R.
    Hyun, M. S.
    HAEMATOLOGICA, 2017, 102 : 793 - 793
  • [44] Daratumumab plus bortezomib-melphalan-prednisone (VMP) in elderly (≥75 y) patients (Pts) with newly diagnosed multiple myeloma (NDMM) ineligible for transplantation (ALCYONE).
    Cavo, Michele
    Iida, Shinsuke
    Blade, Joan
    Mateos, Maria-Victoria
    Lee, Je-Jung
    Garg, Mamta
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [45] PROLONGED THERAPY WITH BORTEZOMIB PLUS MELPHALAN-PREDNISONE (VMP) RESULTS IN IMPROVED QUALITY AND DURATION OF RESPONSE IN THE PHASE III VISTA STUDY IN PREVIOUSLY UNTREATED MULTIPLE MYELOMA (MM)
    Palumbo, A.
    Schlag, R.
    Khuageva, N.
    Shpilberg, O.
    Dimopoulos, M.
    Kropff, M.
    Spicka, I.
    Petrucci, M.
    Delforge, M.
    Mateos, M.
    Esseltine, D.
    Liu, K.
    Deraedt, W.
    Van de Velde, H.
    Richardson, P.
    San-Miguel, J.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 83 - 83
  • [46] Daratumumab plus Bortezomib-Melphalan-Prednisone (VMP) in elderly (≥75 y) patients (Pts) with newly diagnosed multiple myeloma (NDMM) ineligible for transplantation (ALCYONE)
    Cavo, M.
    Iida, S.
    Blade, J.
    Mateos, M-, V
    Lee, J-J
    Garg, M.
    Hungria, V
    Beksac, M.
    Spicka, I
    Knop, S.
    Pour, L.
    Campbell, P.
    Jakubowiak, A.
    Wang, J.
    Wroblewski, S.
    Kobos, R.
    Qi, M.
    San-Miguel, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 182 - 182
  • [47] Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma:: results of a multicenter phase 1/2 study
    Mateos, Maria-Victoria
    Hernandez, Jose-M.
    Hernandez, Miguel-T
    Gutierrez, Norma-C.
    Palomera, Luis
    Fuertes, Marta
    Diaz-Mediavilla, Joaquin
    Lahuerta, Juan-J.
    de la Rubia, Javier
    Terol, Maria-Jose
    Sureda, Ana
    Bargay, Joan
    Ribas, Paz
    de Arriba, Felipe
    Alegre, Adrian
    Oriol, Albert
    Carrera, Dolores
    Garcia-Larana, Jos
    Garcia-Sanz, Ramon
    Blade, Joan
    Prosper, Felipe
    Mateo, Gemma
    Esseltine, Dixie-Lee
    de Velde, Helgi van
    San Miguel, Jesus-F.
    BLOOD, 2006, 108 (07) : 2165 - 2172
  • [48] Cost-Effectiveness Analysis of Adding Daratumumab to a Regimen of Bortezomib, Melphalan, and Prednisone in Newly Diagnosed Multiple Myeloma
    Zeng, Xiaohui
    Liu, Qiao
    Peng, Liubao
    Peng, Ye
    Yi, Lidan
    Luo, Xia
    Li, Sini
    Wan, Xiaomin
    Tan, Chongqing
    ADVANCES IN THERAPY, 2021, 38 (05) : 2379 - 2390
  • [49] Cost-Effectiveness Analysis of Adding Daratumumab to a Regimen of Bortezomib, Melphalan, and Prednisone in Newly Diagnosed Multiple Myeloma
    Xiaohui Zeng
    Qiao Liu
    Liubao Peng
    Ye Peng
    Lidan Yi
    Xia Luo
    Sini Li
    Xiaomin Wan
    Chongqing Tan
    Advances in Therapy, 2021, 38 : 2379 - 2390
  • [50] Cost-effectiveness analysis of daratumumab plus bortezomib, melphalan and prednisone versus bortezomib, melphalan and prednisone in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation
    Xie, Dan
    Zhang, Peng-Fei
    BMJ OPEN, 2025, 15 (02):
12345